The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10625 malaria professionals are enjoying the free benefits of MalariaWorld today


Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality

August 4, 2020 - 15:06 -- Open Access
Osama El-Gendy A, Saeed H, Ali AMA, Zawbaa HM, Gomaa D, Harb HS, Madney YM, Osama H, Abdelrahman MA, Abdelrahim MEA
Vaccine. 2020 Jul 31;38(35):5564-5568

COVID-19 is affecting different countries all over the world with great variation in infection rate and death ratio. Some reports suggested a relation between the Bacillus Calmette-Guérin (BCG) vaccine and the malaria treatment to the prevention of SARS-CoV-2 infection. Some reports related infant's lower susceptibility to the COVID-19.

Evidence for treating malaria with artemisinin-based combination therapy in the first trimester of pregnancy

August 3, 2020 - 16:40 -- Open Access
Gutman JR, Chico RM
Lancet Infect Dis. 2020 Aug; 20(8):880-881

Treatment of malaria during pregnancy requires balancing the need for radical cure while avoiding teratogenic exposure. In The Lancet Infectious Diseases, Makoto Saito and colleagues report the results of a systematic review and meta-analysis that used individual patient data on antimalarial efficacy and tolerability in pregnancy.

NOT Open Access | Evidence of Microbiome-Drug Interactions between the Antimalarial Lumefantrine and Gut Microbiota in Mice

July 7, 2020 - 13:02 -- NOT Open Access
Ippolito MM, Denny JE, Nenortas E, Shapiro TA, Schmidt NW
Am J Trop Med Hyg. 2020 Jul 6

The antimalarial drug lumefantrine (LF) exhibits erratic pharmacokinetics (PK). Intersubject variability might be attributed, in part, to differences in the gut microbiome-mediated drug metabolism. We assessed LF disposition in healthy mice stratified by enterotype to explore associations between the gut microbiota and LF PK. Gut microbiota enterotypes were classified according to abundance and diversity indices from 16S rRNA sequencing.

Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned

June 9, 2020 - 16:13 -- Open Access
Tamiru S. Degaga, Sophie Weston, Kamala Thriemer, et al.
Malaria Journal 2020 19:205, 8 June 2020

International regulatory authorities and funders require that research be disseminated promptly and appropriately to all involved stakeholders. However, following completion of clinical trials participants often either do not receive any feedback or materials provided are not appropriate for the context.

Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

April 13, 2020 - 15:18 -- Open Access
Gaur AH, McCarthy JS, Guy RK, et al.
Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(19)30611-5

(+)-SJ000557733 (SJ733) is a novel, orally bioavailable inhibitor of Plasmodium falciparum ATP4. In this first-in-human and induced blood-stage malaria phase 1a/b trial, we investigated the safety, tolerability, pharmacokinetics, and antimalarial activity of SJ733 in humans.

NOT Open Access | A multicomponent reaction to design antimalarial pyridyl-indole derivatives: Synthesis, biological activities and molecular docking

April 7, 2020 - 06:06 -- NOT Open Access
Elshemy HAH, Zaki MA, Mohamed EI, Khan SI, Lamie PF
Bioorganic Chemistry Volume 97, April 2020, 103673

Using fragment-based design strategy, new pyridyl-indole hybrids 4a–y and indole intermediates 3a–e were synthesized using multicomponent one pot reaction. The synthesized compounds were subjected to screening for antimalarial activity against chloroquine sensitive (D6) and chloroquine resistant (W2) strains of Plasmodium falciparum.

NOT Open Access | Antimalarial Eudesmane Sesquiterpenoids from Dobinea delavayi

April 6, 2020 - 15:26 -- NOT Open Access
Shen Y, Cui SJ, Chen H, Shen L, Wang M, Dong X, Xiao CJ, Jiang B
J Nat Prod. 2020 Apr 1

Eleven new angeloylated eudesmane sesquiterpenoids, dobinins D–N (2, 3, 5, 6, 8, 9, and 11–15), and four known compounds (1, 4, 7, and 10) were isolated from the roots of Dobinea delavayi. A new oxidation product (8a) was also obtained from dobinin H (8). Their structures were elucidated by spectroscopic data and single-crystal X-ray diffraction analyses.

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor

April 6, 2020 - 13:00 -- Open Access
Matthias Rottmann, Brian Jonat, Thomas Spangenberg, et al.
Antimicrob. Agents Chemother. March 2020 64:e02181-19

Antimalarial drug resistance in the Plasmodium falciparum parasite poses a constant challenge for drug development. To mitigate this risk, new antimalarial medicines should be developed as fixed-dose combinations. Assessing the pharmacodynamic interactions of potential antimalarial drug combination partners during early phases of development is essential in developing the targeted parasitological and clinical profile of the final drug product.

NOT Open Access | Classification models for predicting the antimalarial activity against Plasmodium falciparum

March 23, 2020 - 14:16 -- NOT Open Access
Liu Q, Deng J, Liu M
SAR QSAR Environ Res. 2020 Mar 19:1-12

Support vector machine (SVM) and general regression neural network (GRNN) were used to develop classification models for predicting the antimalarial activity against Plasmodium falciparum. Only 15 molecular descriptors were used to build the classification models for the antimalarial activities of 4750 compounds, which were divided into a training set (3887 compounds) and a test set (863 compounds).

NOT Open Access | Effect of drug pressure on promoting the emergence of antimalarial resistant parasites among pregnant women in Ghana

March 19, 2020 - 09:16 -- NOT Open Access
Tornyigah B, Coppée R, Houze P, Kusi KA, Adu B, Quakyi I, Coleman N, Mama A, Deloron P, Anang AK, Clain J, Tahar R, Ofori MF, Ndam NT
Antimicrob Agents Chemother. 2020 Mar 16. pii: AAC.02029-19

Continuous spread of antimalarial drug resistance is a threat to current chemotherapy efficacy. Therefore, characterizing the genetic diversity of drug resistance markers is needed to follow treatment effectiveness and further update control strategies. Here, we genotyped Plasmodium falciparum resistance gene markers associated with sulfadoxine-pyrimethamine (SP) and artemisinin-based combination therapy (ACT) in isolates from pregnant women in Ghana.


Subscribe to RSS - antimalarial